Breaking News
Get 50% Off 0
Get a powerful boost to your portfolio: August's freshest AI-picked stocks
Pick Stocks with AI
Close

Pliant Therapeutics Inc (9PT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.37 +0.03    +2.24%
01/08 - Closed. Currency in EUR
Type:  Equity
Market:  Germany
ISIN:  US7291391057 
S/N:  A2P4YV
  • Volume: 0
  • Bid/Ask: 1.36 / 1.38
  • Day's Range: 1.37 - 1.37
Pliant 1.37 +0.03 +2.24%

Pliant Therapeutics Inc Company Profile

 
Get an in-depth profile of Pliant Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

171

Equity Type

ORD

Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company’s lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Contact Information

Address 331 Oyster Point Boulevard
South San Francisco, 94080
United States
Phone 650 481 6770
Fax -

Top Executives

Name Age Since Title
Bernard Coulie 59 2016 President, CEO & Director
John T. Curnutte 74 2017 Independent Director
Darren S. Cline 61 2023 Independent Director
Hoyoung Huh 56 2017 Independent Chairman & Lead Director
Suzanne L. Bruhn 62 2016 Independent Director
Gayle A. Crowell 74 2019 Independent Director
Steve Edward Krognes 57 2024 Independent Director
Rik Derynck - 2015 Scientific Founder & Member of Scientific Advisory Board
Dean Sheppard - 2015 Scientific Founder & Member of Scientific Advisory Board
Hal Chapman - 2015 Scientific Founder & Member of Scientific Advisory Board
David R. Phillips - - Member of Scientific Advisory Board
Bertus Eksteen - - Member of Scientific Advisory Board
Naftali Kaminski - - Member of Scientific Advisory Board
Brian W. Metcalf 79 - Member of Scientific Advisory Board
David E. I. Pyott 72 2021 Independent Director
Bill Greenlee - - Member of Scientific Advisory Board
Paul W. Noble - - Member of Scientific Advisory Board
Katharine Knobil 61 2022 Independent Director
Thomas A. McCourt 68 2023 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

PLRX Comments

Write your thoughts about Pliant Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email